[Flow cytometric study on the action of progestogen in patients with adenocarcinoma and precancerous lesions of the endometrium].
Synthetic progestogens have been used in 21 patients with endometrial adenocarcinoma and 6 patients with precancerous lesions. During a program of management with medroxyprogesterone acetate (MPA) in an attempt to identify the mechanism by which a remission rate in 30-40% occurred, adenocarcinoma cells were analysed. Histopathologic reactions of endometrial adenocarcinoma treated with MPA 400mg/day through 7 days have been found similar those of normal secretory endometrium such as subnuclear vacuolation, loss of mitotic figure, diminished nuclear size and stromal decidual reaction and regressive changes are highly dose dependent. In detailed analysis of the cell cycle, computerized flow cytometry was employed to quantitate total DNA content following propidium iodide fluorescent staining after RNase treatment. Possible modes of action of MPA on endometrial adenocarcinoma are an increase in the G0+1 fraction corresponding to ploidy reduction. Adenomatous hyperplastic lesions were able to be reversed completely in all patients compared with adenocarcinoma in sixty-six percent.
Nishiya
I
I
Izutsu
T
T
Satoh
K
K
Yoshizumi
N
N
Kurokawa
Y
Y
Kagabu
T
T
D000230:Adenocarcinoma / Q000188:drug therapy* / Q000473:pathology; D000328:Adult; D000368:Aged; D002453:Cell Cycle; D004273:DNA, Neoplasm / Q000032:analysis; D005260:Female; D005434:Flow Cytometry; D006801:Humans; D008525:Medroxyprogesterone / Q000031:analogs & derivatives* / Q000627:therapeutic use; D017258:Medroxyprogesterone Acetate; D008875:Middle Aged; D011230:Precancerous Conditions / Q000188:drug therapy* / Q000473:pathology; D012334:RNA, Neoplasm / Q000032:analysis; D012984:Software; D014594:Uterine Neoplasms / Q000188:drug therapy* / Q000473:pathology
D004273:DNA, Neoplasm; D012334:RNA, Neoplasm; D017258:Medroxyprogesterone Acetate; D008525:Medroxyprogesterone